H型高血压患者代谢性相关指标及MTHFR基因多态性分析(3)
[5]Selhub J，D′Angelo A.Relationship between homocysteine and thrombotic disease[J].Am J Med Sci，1998，316(2)：129-141.
[6]Rodgers GM，Conn MT.Homocysteine，an atherogenic stimulus， reduces protein C activation by arterial and venous endothelial cells[J].Blood，1990，75(4)：895-901.
[7]Qin X，Li J，Cui Y，et al.MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in hypertensive Chinese adults[J]. Nutr J，2012，11：2.
[8]Pool PE.The case for metabolic hypertension：is it time to restructure the hypertension paradigm？[J].Prog Cardiovasc Dis，1993，36(1)：1-38.
[9]Israili ZH，Lyoussi B，Hernández-Hernández R，et al.Metabolic syndrome：treatment of hypertensive patients[J].Am J Ther，2007，14(4)：386-402.
[10]Wilding J，Finer N.Obesity and risk of myocardial infarction：the INTERHEART study[J].Lancet，2006，367 (9516)：1053.
[11]Mancia G，De Backer G，Dominiczak A，et al.2007 Guidelines for the management of arterial hypertension：the task force for the management of arterial hypertensionof the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J].Eur Heart J，2007，28(12)：1462-1536.
[12]Welch GN，Loscalzo J.Homocysteine and atherothrombosis[J].N Engl J Med，1998，338(15)：1042-1050.
[13]Kelly PJ，Rosand J，Kistler JP，et al.Homocysteine，MTHFR 677C→T polymorphism，and risk of ischermic stroke：results of a meta-analysis[J].Neurology，2002，59(4)：529-536.
[14]Den Heijer M，Letwington S，Clarke R.Homoeysteine，MTHFR and risk of venous thrombosis：a meta-analysis of published ep idemiological studies[J].J Thromb Haemost，2005，3(2)：292-299.
[15]Faraci FM，Lentz SR.Hyperhomocysteinemia，oxidative stress，and cerebral vascular dysfunction[J].Stroke，2004，35：345-347.
(收稿日期：2017-05-12 本文編辑：许俊琴), http://www.100md.com(刘玲玲 唐智 肖林)
[6]Rodgers GM，Conn MT.Homocysteine，an atherogenic stimulus， reduces protein C activation by arterial and venous endothelial cells[J].Blood，1990，75(4)：895-901.
[7]Qin X，Li J，Cui Y，et al.MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in hypertensive Chinese adults[J]. Nutr J，2012，11：2.
[8]Pool PE.The case for metabolic hypertension：is it time to restructure the hypertension paradigm？[J].Prog Cardiovasc Dis，1993，36(1)：1-38.
[9]Israili ZH，Lyoussi B，Hernández-Hernández R，et al.Metabolic syndrome：treatment of hypertensive patients[J].Am J Ther，2007，14(4)：386-402.
[10]Wilding J，Finer N.Obesity and risk of myocardial infarction：the INTERHEART study[J].Lancet，2006，367 (9516)：1053.
[11]Mancia G，De Backer G，Dominiczak A，et al.2007 Guidelines for the management of arterial hypertension：the task force for the management of arterial hypertensionof the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J].Eur Heart J，2007，28(12)：1462-1536.
[12]Welch GN，Loscalzo J.Homocysteine and atherothrombosis[J].N Engl J Med，1998，338(15)：1042-1050.
[13]Kelly PJ，Rosand J，Kistler JP，et al.Homocysteine，MTHFR 677C→T polymorphism，and risk of ischermic stroke：results of a meta-analysis[J].Neurology，2002，59(4)：529-536.
[14]Den Heijer M，Letwington S，Clarke R.Homoeysteine，MTHFR and risk of venous thrombosis：a meta-analysis of published ep idemiological studies[J].J Thromb Haemost，2005，3(2)：292-299.
[15]Faraci FM，Lentz SR.Hyperhomocysteinemia，oxidative stress，and cerebral vascular dysfunction[J].Stroke，2004，35：345-347.
(收稿日期：2017-05-12 本文編辑：许俊琴), http://www.100md.com(刘玲玲 唐智 肖林)